Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,975,040
  • Shares Outstanding, K 105,099
  • Annual Sales, $ 14,202 M
  • Annual Income, $ 4,413 M
  • EBIT $ 3,688 M
  • EBITDA $ 4,171 M
  • 60-Month Beta 0.39
  • Price/Sales 5.73
  • Price/Cash Flow 16.50
  • Price/Book 2.56

Options Overview Details

View History
  • Implied Volatility 39.60% (+1.53%)
  • Historical Volatility 28.92%
  • IV Percentile 63%
  • IV Rank 39.60%
  • IV High 60.01% on 04/08/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 7) 15.53 (2.12%)
  • Put/Call Vol Ratio 1.10
  • Today's Volume 3,608
  • Volume Avg (30-Day) 2,460
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 57,719
  • Open Int (30-Day) 53,811
  • Expected Range 717.51 to 748.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 8.07
  • Number of Estimates 6
  • High Estimate 10.82
  • Low Estimate 6.92
  • Prior Year 9.90
  • Growth Rate Est. (year over year) -18.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
726.43 +0.91%
on 01/16/26
821.11 -10.73%
on 01/09/26
-13.32 (-1.78%)
since 12/16/25
3-Month
566.11 +29.49%
on 10/17/25
821.11 -10.73%
on 01/09/26
+163.87 (+28.79%)
since 10/16/25
52-Week
476.49 +53.84%
on 06/05/25
821.11 -10.73%
on 01/09/26
+39.81 (+5.74%)
since 01/16/25

Most Recent Stories

More News
1 Mooning Stock with Exciting Potential and 2 Facing Headwinds

1 Mooning Stock with Exciting Potential and 2 Facing Headwinds

REVG : 67.81 (-1.08%)
FLS : 77.17 (+0.72%)
REGN : 733.04 (-1.20%)
Stocks Settle Mostly Lower as Early Rally Fades

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.34%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.94%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.06%. March E-mini...

MSTR : 173.71 (+1.64%)
B : 48.73 (-1.83%)
HL : 26.54 (+5.23%)
CDE : 22.58 (+6.41%)
JPM : 312.47 (+1.04%)
TXN : 191.58 (+1.30%)
$IUXX : 25,529.26 (-0.07%)
AMGN : 330.41 (+0.12%)
ZNH26 : 111-240s (-0.42%)
ESH26 : 6,976.75s (-0.07%)
GLUE : 23.71 (-1.54%)
STX : 326.23 (+1.85%)
Why Regeneron (REGN) Stock Is Trading Up Today

Why Regeneron (REGN) Stock Is Trading Up Today

REGN : 733.04 (-1.20%)
Regeneron Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know

Regeneron Pharmaceuticals will release its fourth-quarter earnings later this month, and analysts anticipate a double-digit profit dip.

XLV : 155.74 (-0.78%)
$SPX : 6,940.01 (-0.06%)
REGN : 733.04 (-1.20%)
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026

TARRYTOWN, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2025 financial and operating results...

REGN : 733.04 (-1.20%)
3 Reasons to Avoid REGN and 1 Stock to Buy Instead

3 Reasons to Avoid REGN and 1 Stock to Buy Instead

REGN : 733.04 (-1.20%)
Stocks Fall Slightly in Thin Holiday Trade

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.14%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.20%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.25%. March E-mini...

C : 118.04 (+0.49%)
RARE : 22.49 (-4.30%)
HL : 26.54 (+5.23%)
SLB : 46.73 (+0.34%)
$IUXX : 25,529.26 (-0.07%)
ZNH26 : 111-240s (-0.42%)
OXY : 42.70 (-1.09%)
ESH26 : 6,976.75s (-0.07%)
FANG : 151.28 (+0.30%)
JBL : 251.29 (-0.75%)
$DOWI : 49,359.33 (-0.17%)
SPY : 691.66 (-0.08%)
Stocks Slip as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.11%. March E-mini S&P futures...

C : 118.04 (+0.49%)
RARE : 22.49 (-4.30%)
SLB : 46.73 (+0.34%)
$IUXX : 25,529.26 (-0.07%)
ZNH26 : 111-240s (-0.42%)
OXY : 42.70 (-1.09%)
ESH26 : 6,976.75s (-0.07%)
FANG : 151.28 (+0.30%)
$DOWI : 49,359.33 (-0.17%)
SPY : 691.66 (-0.08%)
DIA : 493.42 (-0.21%)
INSM : 161.42 (+1.35%)
3 Cash-Heavy Stocks We Approach with Caution

3 Cash-Heavy Stocks We Approach with Caution

FBNC : 57.92 (+0.68%)
BK : 121.33 (-2.13%)
REGN : 733.04 (-1.20%)
Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent...

SAN.FP : 80.780 (-1.04%)
REGN : 733.04 (-1.20%)
SNY : 46.59 (-1.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 768.60
2nd Resistance Point 758.85
1st Resistance Point 745.94
Last Price 733.04
1st Support Level 723.28
2nd Support Level 713.53
3rd Support Level 700.62

See More

52-Week High 821.11
Last Price 733.04
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Fibonacci 38.2% 608.13
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar